Anticancer Drug Development Guide PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Anticancer Drug Development Guide PDF full book. Access full book title Anticancer Drug Development Guide by Beverly A. Teicher. Download full books in PDF and EPUB format.
Author: Beverly A. Teicher
Publisher: Springer Science & Business Media
ISBN: 1592597394
Category : Medical
Languages : en
Pages : 514
Get Book Here
Book Description
This unique volume traces the critically important pathway by which a "molecule" becomes an "anticancer agent. " The recognition following World War I that the administration of toxic chemicals such as nitrogen mustards in a controlled manner could shrink malignant tumor masses for relatively substantial periods of time gave great impetus to the search for molecules that would be lethal to specific cancer cells. Weare still actively engaged in that search today. The question is how to discover these "anticancer" molecules. Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval, Second Edition describes the evolution to the present of preclinical screening methods. The National Cancer Institute's high-throughput, in vitro disease-specific screen with 60 or more human tumor cell lines is used to search for molecules with novel mechanisms of action or activity against specific phenotypes. The Human Tumor Colony-Forming Assay (HTCA) uses fresh tumor biopsies as sources of cells that more nearly resemble the human disease. There is no doubt that the greatest successes of traditional chemotherapy have been in the leukemias and lymphomas. Since the earliest widely used in vivo drug screening models were the murine L 1210 and P388 leukemias, the community came to assume that these murine tumor models were appropriate to the discovery of "antileukemia" agents, but that other tumor models would be needed to discover drugs active against solid tumors.
Author: Beverly A. Teicher
Publisher: Springer Science & Business Media
ISBN: 1592597394
Category : Medical
Languages : en
Pages : 514
Get Book Here
Book Description
This unique volume traces the critically important pathway by which a "molecule" becomes an "anticancer agent. " The recognition following World War I that the administration of toxic chemicals such as nitrogen mustards in a controlled manner could shrink malignant tumor masses for relatively substantial periods of time gave great impetus to the search for molecules that would be lethal to specific cancer cells. Weare still actively engaged in that search today. The question is how to discover these "anticancer" molecules. Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval, Second Edition describes the evolution to the present of preclinical screening methods. The National Cancer Institute's high-throughput, in vitro disease-specific screen with 60 or more human tumor cell lines is used to search for molecules with novel mechanisms of action or activity against specific phenotypes. The Human Tumor Colony-Forming Assay (HTCA) uses fresh tumor biopsies as sources of cells that more nearly resemble the human disease. There is no doubt that the greatest successes of traditional chemotherapy have been in the leukemias and lymphomas. Since the earliest widely used in vivo drug screening models were the murine L 1210 and P388 leukemias, the community came to assume that these murine tumor models were appropriate to the discovery of "antileukemia" agents, but that other tumor models would be needed to discover drugs active against solid tumors.
Author: Elizabeth Garrett-Mayer
Publisher: Springer Science & Business Media
ISBN: 1441973583
Category : Medical
Languages : en
Pages : 673
Get Book Here
Book Description
A practical guide to the design, conduction, analysis and reporting of clinical trials with anticancer drugs.
Author: Daniel Budman
Publisher: Lippincott Raven
ISBN: 9780781740104
Category : Medical
Languages : en
Pages : 502
Get Book Here
Book Description
Perhaps no area of pharmacology has progressed further or faster than that of anticancer drugs. With this concise and informative resource, you'll explore the full spectrum of anticancer drug evolution -- from research and development, through clinical trials, to licensure and utilization.
Author: Bruce C. Baguley
Publisher: Elsevier
ISBN: 0080490441
Category : Medical
Languages : en
Pages : 411
Get Book Here
Book Description
Here in a single source is a complete spectrum of ideas on the development of new anticancer drugs. Containing concise reviews of multidisciplinary fields of research, this book offers a wealth of ideas on current and future molecular targets for drug design, including signal transduction, the cell division cycle, and programmed cell death. Detailed descriptions of sources for new drugs and methods for testing and clinical trial design are also provided. - One work that can be consulted for all aspects of anticancer drug development - Concise reviews of research fields, combined with practical scientific detail, written by internationally respected experts - A wealth of ideas on current and future molecular targets for drug design, including signal transduction, the cell division cycle, and programmed cell death - Detailed descriptions of the sources of new anticancer drugs, including combinatorial chemistry, phage display, and natural products - Discussion of how new drugs can be tested in preclinical systems, including the latest technology of robotic assay systems, cell culture, and experimental animal techniques - Hundreds of references that allow the reader to access relevant scientific and medical literature - Clear illustrations, some in color, that provide both understanding of the field and material for teaching
Author: Ashkan Emadi, MD, PhD
Publisher: Springer Publishing Company
ISBN: 0826162045
Category : Medical
Languages : en
Pages : 313
Get Book Here
Book Description
Cancer Pharmacology: An Illustrated Manual of Anticancer Drugs provides a one-stop guide to the essential basic and clinical science of all the effective, life-prolonging drug therapies in oncology. From traditional cytotoxic agents to targeted genomic, epigenomic, hormonal, and immunotherapeutic agents, this book covers the staggering advances in cancer pharmacology that are propelling new standards of care for common and uncommon malignancies. Beautifully illustrated throughout, each chapter contains visually engaging figures detailing the tumor microenvironment, chemical structures of agents, pharmacodynamics, pharmacokinetics, pharmacogenomic, and molecular properties of the various agents, and their mechanisms of action. As the first illustrated book of its kind, this highly visual text uses a uniform approach to each cancer drug class and agent presented in the book, and covers alkylating agents, antimetabolites, antimitotics, epigenetic modulators, hormonal agents, targeted therapies, monoclonal antibodies, immunotherapeutic agents, and much more. Flow diagrams, clinical tables, and bulleted text further explain important information pertaining to each cancer drug class including their indications, mechanisms of action, potential adverse reactions, dosing and dose adjustments, and safety monitoring. Organized in an easyto- digest format and replete with detailed images, clinical pearls, and end of chapter Q&As, this evidence-based reference presents all major classes, agents, targets, and approaches to cancer pharmacotherapy. Whether you are a trainee, a clinical scientist, or a clinician in practice, the book is an ideal reference. It presents challenging information in an instructional way, illustrates key concepts for ease of retention, and poses tough questions so readers can problem solve potential scenarios and test their pharmacologic acumen. Written by leading experts in oncopharmacology, this first-of-its kind manual is a “must have” for anyone involved in the basic, translational, or clinical aspects of oncology and hematology including clinicians, pharmacists, nurses, and trainees. KEY FEATURES: Includes visual depictions of chemical structures, pharmacokinetics, pharmacodynamics, and pharmacogenomics associated with each class of agents Describes how chemotherapy, targeted therapy, immunotherapy, and hormonal therapy work and why they are expected to work adjuvantly, neoadjuvantly, and in combination with other modalities Over 100 highly stylized images and numerous comprehensive tables Covers challenges related to drug development, drug approval, and regulatory issues in relation to anticancer treatments All chapters conclude with clinical pearls and detailed clinical Q&As with descriptive rationales Purchase includes access to the ebook for use on most mobile devices or computers
Author: William Figg
Publisher: Humana Press
ISBN: 9781588291776
Category : Medical
Languages : en
Pages : 623
Get Book Here
Book Description
Leading investigators synthesize the entire laboratory and clinical process of developing anticancer drugs to create a single indispensable reference that covers all the steps from the identification of cancer-specific targets to phase III clinical trials. These expert authors provide their best guidance on a wide variety of issues, including clinical trial design, preclinical screening, and the development and validation of bioanalytic methods. The chapters on identifying agents to test in phase III trials and on trial design for the approval of new anticancer agents offer a unique roadmap for moving an agent to NDA submission.
Author: Beverly A. Teicher
Publisher: Springer Science & Business Media
ISBN: 1461581524
Category : Medical
Languages : en
Pages : 315
Get Book Here
Book Description
Experienced cancer researchers from pharmaceutical companies, government laboratories, and academia comprehensively review and describe the arduous process of cancer drug discovery and approval. They focus on using preclinical in vivo and in vitro methods to identify molecules of interest, detailing the targets and criteria for success in each type of testing and defining the value of the information obtained from the various tests. They also define each stage of clinical testing, explain the criteria for success, and outline the requirements for FDA approval. A companion volume by the same editor (Cancer Therapeutics: Experimental and Clinical Agents) reviews existing anticancer drugs and potential anticancer therapies. These two volumes in the Cancer Drug Discovery and Development series reveal how and why molecules become anticancer drugs and thus offer a blueprint for the present and the future of the field.
Author: National Academies of Sciences, Engineering, and Medicine
Publisher: National Academies Press
ISBN: 0309457971
Category : Medical
Languages : en
Pages : 145
Get Book Here
Book Description
Advances in cancer research have led to an improved understanding of the molecular mechanisms underpinning the development of cancer and how the immune system responds to cancer. This influx of research has led to an increasing number and variety of therapies in the drug development pipeline, including targeted therapies and associated biomarker tests that can select which patients are most likely to respond, and immunotherapies that harness the body's immune system to destroy cancer cells. Compared with standard chemotherapies, these new cancer therapies may demonstrate evidence of benefit and clearer distinctions between efficacy and toxicity at an earlier stage of development. However, there is a concern that the traditional processes for cancer drug development, evaluation, and regulatory approval could impede or delay the use of these promising cancer treatments in clinical practice. This has led to a number of effortsâ€"by patient advocates, the pharmaceutical industry, and the Food and Drug Administration (FDA)â€"to accelerate the review of promising new cancer therapies, especially for cancers that currently lack effective treatments. However, generating the necessary data to confirm safety and efficacy during expedited drug development programs can present a unique set of challenges and opportunities. To explore this new landscape in cancer drug development, the National Academies of Sciences, Engineering, and Medicine developed a workshop held in December 2016. This workshop convened cancer researchers, patient advocates, and representatives from industry, academia, and government to discuss challenges with traditional approaches to drug development, opportunities to improve the efficiency of drug development, and strategies to enhance the information available about a cancer therapy throughout its life cycle in order to improve its use in clinical practice. This publication summarizes the presentations and discussions from the workshop.
Author: Kenneth J. Olivier, Jr.
Publisher: John Wiley & Sons
ISBN: 111906080X
Category : Medical
Languages : en
Pages : 474
Get Book Here
Book Description
Providing practical and proven solutions for antibody-drug conjugate (ADC) drug discovery success in oncology, this book helps readers improve the drug safety and therapeutic efficacy of ADCs to kill targeted tumor cells. • Discusses the basics, drug delivery strategies, pharmacology and toxicology, and regulatory approval strategies • Covers the conduct and design of oncology clinical trials and the use of ADCs for tumor imaging • Includes case studies of ADCs in oncology drug development • Features contributions from highly-regarded experts on the frontlines of ADC research and development
Author: Asfar Azmi
Publisher: Academic Press
ISBN: 9780128147047
Category : Business & Economics
Languages : en
Pages : 0
Get Book Here
Book Description
Animal Models in Cancer Drug Discovery brings forward the most cutting-edge developments in tumor model systems for translational cancer research. The reader can find under this one volume virtually all types of existing and emerging tumor models in use by the research community. This book provides a deeper insight on how these newer models could de-risk modern drug discovery. Areas covered include up to date information on latest organoid derived models and newer genetic models. Additionally, the book discusses humanized animal tumor models for cancer immunotherapy and how they leverage personalized therapies. The chapter on larger animal, canine models and their use in and their use in pre-investigational new drug (pre-IND) development makes the volume unique. Unlike before, the incorporation of several simplified protocols, breeding methodologies, handling and assessment procedures to study drug intervention makes this book a must read. Animal Models in Cancer Drug Discovery is a valuable resource for basic and translational cancer researchers, drug discovery researchers, contract research organizations, and knowledge seekers at all levels in the biomedical field.
